Passanisi, Stefano http://orcid.org/0000-0002-4369-7798
Lombardo, Fortunato http://orcid.org/0000-0002-7081-5884
Mameli, Chiara http://orcid.org/0000-0002-6768-3411
Bombaci, Bruno http://orcid.org/0000-0001-8664-1025
Macedoni, Maddalena http://orcid.org/0000-0002-4241-256X
Zuccotti, Gianvincenzo http://orcid.org/0000-0002-2795-9874
Dovc, Klemen http://orcid.org/0000-0001-9201-2145
Battelino, Tadej http://orcid.org/0000-0002-0273-4732
Salzano, Giuseppina http://orcid.org/0000-0003-2180-4510
Delvecchio, Maurizio http://orcid.org/0000-0002-1528-0012
Funding for this research was provided by:
Slovenian Research and Innovation Agency grant (#P3-0343, #P3-0343)
Article History
Received: 11 August 2023
Accepted: 20 October 2023
First Online: 1 December 2023
Declarations
:
: Tadej Battelino has served on advisory panels of Novo Nordisk, Sanofi, Eli Lilly, Boehringer, Medtronic, and Indigo Diabetes. He has received honoraria for participating in the speaker’s bureaux of Eli Lilly, Novo Nordisk, Medtronic, Abbott, Sanofi, Aventis, Astra Zeneca, and Roche. Tadej Battelino’s institution has received research grant support from Abbott, Medtronic, Novo Nordisk, Sanofi, Novartis, Sandoz, and Zealand Pharma, the Slovenian Research Agency, the National Institutes of Health, and the European Union. The other authors (Stefano Passanisi, Fortunato Lombardo, Chiara Mameli, Bruno Bombaci, Maddalena Macedoni, Gianvincenzo Zuccotti, Klemen Dovc, Giuseppina Salzano and Maurizio Delvecchio) do not declare any competing interest. Since the paper was submitted, Maurizio Delvecchio’s affiliation has changed from Metabolic Disorders and Clinical Genetics, “Giovanni XXIII” Children’s Hospital, AOU Policlinico-Giovanni XXIII, Bari, Italy, to Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy (his current affiliation).
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.